Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease

Autor:	S A McCartney, Marion G. Macey, David S. Rampton, E Carty
Rok vydání:	2000
Předmět:	medicine.medical_specialty Hepatology biology business.industry Thromboxane Gastroenterology medicine.disease Inflammatory bowel disease Thromboxane B2 chemistry.chemical_compound Endocrinology Eicosanoid chemistry Internal medicine medicine biology.protein Pharmacology (medical) Platelet Platelet activation Thromboxane-A synthase Prostaglandin E2 business medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 14:807-817
ISSN:	0269-2813
DOI:	10.1046/j.1365-2036.2000.00779.x
Popis:	Background: Thromboxanes, prostaglandins, reactive oxygen metabolites and pro-inflammatory cytokines are produced in excess in inflammatory bowel disease. Preliminary reports suggest that ridogrel, a thromboxane synthesis inhibitor and receptor blocker, may have therapeutic benefits in ulcerative colitis. Aims: To investigate the anti-inflammatory profile of ridogrel. Methods: The effects of ridogrel on the production of eicosanoids, reactive oxygen metabolites and cytokines by cultured inflamed colorectal mucosal biopsies were made using ELISA and chemiluminescence, reactive oxygen metabolite generation in a cell-free system, and platelet activation using flow cytometry. The effects of oral ridogrel on mucosal release of eicosanoids in two patients with active ulcerative colitis were assessed using rectal dialysis. Results: Ridogrel significantly reduced the release of thromboxane B2, but not prostaglandin E2 or tumour necrosis factor-α, from biopsies (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e6ccd04b6edd5e3259beba0408b52524 https://doi.org/10.1046/j.1365-2036.2000.00779.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.